Slomin

Quick links to important sections

Slomin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Slomin

Property Description
Active Ingredient Oxymetazoline
Form Topical solution, spray, or gel
Pharmacological Class Adrenergic Agonist / Sympathomimetic
General Purpose Reducing swelling and redness
Origin Synthetic

Slomin is a common proprietary name for a medicine containing the active ingredient Oxymetazoline. It is classified as an adrenergic agonist (or sympathomimetic), which means it mimics the effects of natural adrenaline on certain body receptors. This classification is recognized for providing immediate local effects.

This medication is a synthetic compound, specifically an imidazole derivative, designed for rapid and local action. Slomin is generally positioned as an over-the-counter (OTC) topical treatment often used for temporary symptoms. Its classification as an alpha-agonist means its fundamental purpose is to selectively target receptors that control the constriction of blood vessels.


What Is Slomin’s Composition and Form?

Slomin is typically a single-ingredient medicine, containing Oxymetazoline as the sole active pharmaceutical component responsible for the therapeutic effect. It is predominantly offered as a topical dosage form, such as a nasal spray solution, emphasizing ease of self-administration.

The route of administration is consistently topical, applied directly to the affected external surface, such as the nasal lining (intranasal) or the eye (ophthalmic). This direct delivery method ensures the active ingredient is highly concentrated exactly where it is needed, distinguishing it from medicines taken by mouth, which are distributed throughout the body.


How Does Slomin Provide Its General Benefit?

The general benefit of Slomin comes from its core mechanism principle: causing vasoconstriction, or the narrowing of local blood vessels. When applied, Oxymetazoline activates alpha-adrenergic receptors on the blood vessel walls in the local tissue, causing them to physically constrict or tighten.

This physical narrowing of the vessels results in a reduction in blood flow and physical swelling in the affected area. Therefore, its general purpose is to provide relief for symptoms like nasal congestion by shrinking the swollen nasal turbinates or to reduce visible redness by constricting tiny capillaries beneath the skin surface, providing localized relief.

Regulatory References

  1. MedlinePlus - Oxymetazoline

What side effects are possible with Slomin?

Possible Side Effects and Safety Information

The official safety information for Slomin (Oxymetazoline), an adrenergic agonist, details adverse reactions organized by frequency and the organ systems affected, as documented in government regulatory sources (e.g., FDA DailyMed, EMA SmPC).

Common and Expected Adverse Reactions

Adverse reactions that are frequently observed are related to the site of application. These typically involve the Respiratory, Thoracic, and Mediastinal Disorders system-organ class and are classified as common. They include transient discomfort, such as burning, stinging, or dryness of the nasal mucosa, and occasional sneezing.

Systemic and Serious Safety Considerations

Systemic effects, which involve the Nervous System and Cardiac/Vascular Systems, are documented but generally classified as rare when the product is used as directed. These potential effects include headache, insomnia, palpitations, and increased blood pressure (hypertension).

Accidental ingestion, particularly by young children (aged 5 years and under), is officially associated with severe systemic reactions requiring hospitalization. Documented serious adverse events resulting from ingestion include coma, bradycardia (slow heart rate), and respiratory depression.

Duration-Related and Population-Specific Safety Patterns

The primary duration-related safety pattern is the development of Rhinitis Medicamentosa, or rebound congestion. Regulatory documents explicitly state that this worsening or recurrence of nasal congestion may occur with prolonged or excessive use, emphasizing that application duration must be limited.

Safety restrictions are noted for patients with pre-existing conditions that are sensitive to vasoconstrictors. Precautions are advised for individuals with heart disease, high blood pressure, diabetes, thyroid disease, or trouble urinating due to an enlarged prostate gland. Use is restricted in patients with conditions like narrow-angle glaucoma or those concurrently using Monoamine Oxidase Inhibitors (MAOIs), due to the risk of exacerbating blood pressure issues.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation classifies the primary risk of Slomin (Oxymetazoline) overdose as systemic toxicity following accidental ingestion of the topical solution. Serious harm and life-threatening events have been reported following systemic exposure.

Documented Overdose Manifestations

System Affected Recognized Clinical Signs (Regulatory Basis)
Central Nervous System Sedation, lethargy, stupor, confusion, and coma.
Cardiovascular System Bradycardia (slow heart rate), tachycardia (fast heart rate), hypotension, and hypertension.

Required Emergency Actions

The official prescribing information mandates urgent action for any suspected systemic exposure. Life-threatening events reported in regulatory sources include respiratory depression and severe bradycardia, constituting serious harm requiring hospitalization.

Immediate Action Statement:

  • Seek emergency medical attention immediately and contact a Poison Control Center right away if the product is swallowed.
  • Accidental ingestion by children ≤ 5 years of age is associated with severe adverse reactions, even from very small amounts (1–2 mL), requiring immediate care.

Management Note: Treatment is symptomatic and supportive. Regulatory documents do not list a specific chemical antidote for Oxymetazoline overdose.

Therapeutic Uses of Slomin

What Slomin Treats: Main Uses and Benefits

Slomin is indicated for the management of various neurological and movement-related conditions. The treatment is intended to assist in managing symptoms that may affect daily activities. Slomin is typically used in clinical scenarios to address chronic sialorrhea, increased muscle stiffness in the upper limbs due to spasticity, abnormal head position and neck pain associated with cervical dystonia, and abnormal spasm of the eyelids known as blepharospasm.

The treatment is intended to support improved functional ability and manage the physical manifestations of these conditions through symptom management.

Quick Fact: Relief for Muscle Spasms

Eligibility and Restrictions for Use

Slomin's eligibility for use is defined by specific regulatory rules concerning age, medical history, and physiological status, as documented in official government prescribing information.

Contraindicated Populations

The medicine is contraindicated and must not be used in the following patient groups:

  • Patients with a known hypersensitivity to the formulation components.
  • Individuals with an active infection at the site where the medicine is to be administered.
  • Patients with pre-existing neuromuscular junction disorders, such as Myasthenia Gravis or Lambert-Eaton Syndrome.

Age-Related Eligibility Rules

Population Approved Minimum Age Restriction Status
Adults 18 years Eligible for all approved uses.
Pediatric (Specific Uses) 2 years Approved for chronic sialorrhea and spasticity indications.
Infants Under 2 years Safety and effectiveness not established for any indication.

Conditional Use Restrictions

Use is restricted and requires caution in patients with pre-existing pulmonary compromise or those with bleeding tendencies or receiving anticoagulants. For women who are pregnant or breastfeeding, use is restricted as no adequate studies exist; the official recommendation requires that the potential benefit must be weighed against the potential risk to the fetus.

What should I know about interactions with other medicines?

Slomin Interactions with other medicines and products

The official regulatory documents for Slomin (Oxymetazoline) define its interaction profile primarily through pharmacodynamic mechanisms, which relate to the product's function as an adrenergic agonist. No metabolic (CYP enzyme) or transporter-mediated pharmacokinetic interactions are explicitly documented in regulatory labeling.


Interaction Scope

Property Regulatory Statement
Medicinal product categories with documented interactions Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), Nonselective Beta-Adrenergic Antagonists, Anti-hypertensive drugs, Cardiac Glycosides.
Mechanistic basis of interactions Pharmacodynamic Interaction: Potentiation of sympathomimetic effects or antagonism of blood pressure-regulating effects.
Timing-based interaction rules Mandatory 24-hour discontinuation of other Oxymetazoline-containing products is required before administering specific combination formulations.

Interaction Classifications (High-Level)

Classification Regulatory Statement
Interaction severity classification Not Recommended Combinations (MAOIs, TCAs, Nonselective Beta-Blockers). Use with Caution (Anti-hypertensives, Cardiac Glycosides).
Interaction-context constraints Use caution when co-administering with Anti-hypertensives, Beta-blockers, and/or Cardiac Glycosides due to the potential impact on blood pressure control.

Official interaction statements:

  • Co-administration with Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Nonselective Beta-Adrenergic Antagonists is not recommended due to a documented risk of severe hypertension.
  • The effectiveness of certain anti-hypertensive drugs may be reduced during co-administration with Oxymetazoline.
  • The risk of dysrhythmias may increase when Oxymetazoline is used with Cardiac Glycosides.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define the product's interaction structure by classifying medicines that significantly amplify its adrenergic action or medicines whose effects may be neutralized. This profile establishes clear, mandatory restrictions against certain combinations and requires specific timing separation for other Oxymetazoline products.

Mechanism of Action

Targeting Alpha-1 Adrenergic Receptors

The mechanism involves direct agonism of Alpha-1 Adrenergic Receptors (alpha1), which are densely located on the vascular smooth muscle cells of local blood vessels. This receptor activation initiates the Gq-protein signaling cascade, linking the drug's binding to the cellular response of contraction.


Inducing Local Vasoconstriction and Decreased Tissue Volume

The receptor activation causes a rapid increase in intracellular calcium ions ( Ca^2+) within the vessel wall cells. This surge of Ca^2+ triggers the physical contraction of the vascular smooth muscle, resulting in vasoconstriction (narrowing of the vessels). This reduction in local blood volume and flow is the core physiological mechanism that decreases the volume of the local tissue structure.


Understanding Mechanistic Constraint (Tachyphylaxis)

The continuous activation of the alpha1 receptors represents a key mechanistic constraint: tachyphylaxis (receptor desensitization). This physiological adaptation involves the receptors becoming less responsive to the drug over time, functionally reducing the efficacy of the vasoconstrictive mechanism. This constraint introduces a risk of rebound vasodilation when signaling is ceased, due to altered regulation of vascular tone.

Dosage and Administration Information

How to use Slomin — Administration Guidelines

Slomin is administered exclusively via localized Intramuscular (IM) or Intradermal injection by a qualified healthcare professional. Its use is strictly procedural, governed by established protocols regarding dosing and frequency.

Property Instruction (Label-Based)
Route of Administration Localized Intramuscular or Intradermal injection, depending on the target tissue (muscle vs. gland).
Dosing Schedule Measured in proprietary Units. Doses vary by indication, from small, site-specific doses up to approximately 400 Units total per session for extensive spasticity.
Preparation Mandatory reconstitution of the lyophilized powder using sterile, preservative-free sodium chloride solution is required immediately prior to administration.
Frequency Pattern Intermittent and cyclic use. A strict minimum interval of 12 weeks must pass between repeat injection courses for all approved indications.
Population Rules Older adults may require lower starting doses. Separate, age- and weight-based protocols exist for certain pediatric uses.
Special Conditions Administration often requires technical guidance, such as ultrasound or electromyography (EMG), to ensure accurate delivery into the target site.

The procedural structure of Slomin's use dictates that it is a specialized procedure, not a routine daily medication. This ensures that the treatment is managed under specialist supervision with defined schedules and site-specific targeting, adhering precisely to the defined constraints on total dose and minimum time interval between treatments.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Slomin (Oxymetazoline)


Evidence for Acquired Blepharoptosis (Droopy Eyelid)

Research examining Slomin's ophthalmic use was evaluated in Randomized Controlled Trials (RCTs). These short-term studies were used in research exploring how symptoms change over time and often included a non-medicated vehicle (placebo) in the trial design. The research focused on adults with acquired blepharoptosis (low-lying upper eyelid). The study outcomes examined were objective measurements of eyelid position, such as the Marginal Reflex Distance 1 (MRD1), as well as how patients reported their experience.

The studies report how symptoms evolved in the observed populations by documenting measurements of changes in eyelid height (MRD1) at pre-specified follow-up points (e.g., 6 weeks). Findings describe patterns observed in the studies related to the proportion of individuals who achieved a predefined level of change in eyelid height.


Evidence for Persistent Facial Erythema (Rosacea-Related Redness)

Slomin's dermatological application was evaluated in large-scale Randomized Controlled Trials (RCTs) that often included a vehicle. These studies explored outcomes linked to inflammatory or irritative states, focusing specifically on persistent facial redness. The main study outcomes that research examined included using standardized scales like the Clinician Erythema Assessment (CEA) score and patient-reported outcomes describing perceived discomfort. Findings help contextualize patient-reported experiences during the study period, and research describes patterns related to how redness levels evolved in the observed adult populations.


Evidence for Acute Nasal Congestion (OTC Use)

The intranasal use of Slomin was studied for outcomes related to physical discomfort associated with acute changes, such as those due to the common cold or seasonal allergies. Research examined short-term symptom changes through RCTs. Studies monitored both subjective outcomes related to physical discomfort and objective physiological measurements of nasal airflow (using techniques like rhinomanometry).

Studies report how symptoms evolved in the observed populations, indicating that changes may be observed in a short timeframe after administration. Trials documented measurements of the time-course of measured changes on nasal airflow and subjective congestion ratings following intranasal administration.


What Research Remains Inconsistent or Limited

Across the research base, a common limitation is the focus on short-term changes, meaning long-term effects are not fully established for sustained use. For intranasal use, the inconsistency of reported outcomes related to the risk of rebound congestion represents a significant area of uncertainty. Furthermore, subgroup findings are uncertain regarding patients with severe underlying conditions or those in pediatric populations, as these groups were often narrowly defined or excluded from the main research.

Key Studies & References

  1. Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results

Frequently Asked Questions (FAQ)

Common questions about Slomin (FAQ)


Q: How quickly should I expect to feel the effects of Slomin?

According to official product information for the nasal preparations, the initial effects of Slomin, such as relief from congestion, are expected to begin working within a few minutes after administration.


Q: Can pregnant women safely take Slomin?

Official regulatory documents indicate that adequate and well-controlled studies on the use of Slomin during pregnancy have not been conducted. Official labeling recommends that individuals who are pregnant or planning to become pregnant consult a health professional prior to use.


Q: Can I take other supplements, like vitamins, with Slomin?

Regulatory documents list specific interactions with certain prescription medications, such as MAOIs. They do not generally list specific interactions with common vitamin or mineral supplements. Official resources suggest consulting a healthcare professional regarding all products and supplements being considered for co-administration.


Q: Can elderly patients take Slomin without increased risk?

Official labeling advises that precautions should be taken for patients with pre-existing conditions that are more common in older adults, such as high blood pressure or heart disease. All individuals with underlying health issues, particularly those sensitive to vasoconstrictors, are advised to exercise caution.


Q: Can breastfeeding mothers use Slomin?

It is not known if the active ingredient in Slomin is excreted into human breast milk. Due to this uncertainty, official warnings recommend that individuals who are breastfeeding consult a health professional prior to use.


Q: Is Slomin only for short-term treatment?

Yes, for common nasal preparations, official instructions strictly limit use. The product should not be used for more than three consecutive days, as indicated in official labeling. Using it too frequently or for prolonged periods can lead to a condition called Rhinitis Medicamentosa, causing congestion to worsen or recur.


Q: Can Slomin be taken with common pain relievers like ibuprofen?

The primary drug interaction warnings focus on medicines that affect blood pressure, such as MAOIs and tricyclic antidepressants. Simple pain relievers like ibuprofen are generally not listed as a contraindication in regulatory texts, but consultation with a health professional is advised regarding any specific drug combination.


Q: How long does Slomin stay in your system after stopping it?

Official pharmacological data indicates that the drug has an elimination half-life of approximately five to six hours. The half-life refers to the time it takes for the concentration of the medication in the body to decrease by half.


Q: Is Slomin appropriate for use in children?

The appropriateness of use depends on the child's age. For nasal spray products, children aged 6 to under 12 years should only use the medicine with adult supervision. For any children under 6 years of age, official instructions state that consultation with a doctor is required before use.


Q: Does Slomin interact with birth control pills?

Official drug labels primarily warn about interactions with prescription medicines that affect blood pressure or heart function. Hormonal contraceptives (birth control pills) are not typically listed as a contraindication for the use of topical Slomin, but consultation with a healthcare professional is recommended regarding any potential co-administered medications.


Q: What should I do if I miss a dose of Slomin?

For as-needed products like Slomin, if a dose is missed, it can be used as soon as the user remembers. If it is almost time for the next scheduled dose, official guidelines state that only that dose should be used. The product label cautions against using double or extra doses to make up for the missed one.


Q: Is it normal to feel a little dizzy when first starting Slomin?

Dizziness is documented as a possible systemic adverse reaction, though it is considered rare when the product is used as directed. If persistent dizziness or other signs of a serious adverse event occur, it is recommended to stop use and seek medical attention.


Q: Can Slomin affect my sleep patterns?

Rare systemic side effects of Slomin, which primarily occur when the drug is absorbed into the bloodstream, may include insomnia (trouble sleeping). If persistent changes or disturbance in sleep patterns occur, it is advisable to consult a healthcare professional.


Q: Can Slomin make me feel more tired during the day?

Drowsiness or fatigue is not typically listed as a common or expected side effect in the official regulatory documents for Slomin. Reported systemic effects, though rare, tend to be stimulating (like insomnia) rather than sedating.


Q: Is Slomin a controlled substance?

No, the active ingredient in Slomin, oxymetazoline, is not classified as a controlled substance under the U.S. Drug Enforcement Administration (DEA) scheduling.


Q: What happens if I stop taking Slomin suddenly?

If Slomin is used too frequently or for too long, stopping the medication can cause the original nasal congestion to worsen or recur severely. This rebound effect is the main concern when discontinuing the product after prolonged use.


Q: Does Slomin affect my ability to drive or operate machinery?

While the drug is generally localized, rare systemic side effects like headache or dizziness can occur. If any effects that temporarily impair the ability to think clearly or react quickly occur, it is recommended to avoid driving or operating machinery.


Q: Is Slomin available as a generic version?

Yes, the active ingredient in Slomin, oxymetazoline, is widely available in numerous generic and store-brand over-the-counter products across different jurisdictions.


Q: Why do some people experience stomach upset with Slomin?

Stomach upset is not commonly reported as a normal side effect for the topical forms of Slomin. The regulatory documents emphasize that accidental ingestion, particularly by young children, can cause severe systemic reactions, but this is a misuse warning, not a common side effect.


Q: Are there different strengths or formulations of Slomin?

Yes, Slomin is available in multiple topical formulations, including nasal sprays, eye drops, and creams, and in different concentrations to address various approved conditions. A healthcare provider will determine the appropriate formulation.


Q: Is Slomin known to interact with herbal supplements like St. John's Wort?

Official warnings strongly advise against using Slomin with prescription medications that increase blood pressure, such as MAOIs. Consultation with a healthcare professional is necessary regarding the use of specific herbal supplements, as some may have similar effects that could potentially interact with Slomin's sympathomimetic action.


Q: Is Slomin a relatively new drug or has it been around for a while?

The active ingredient, oxymetazoline, is an older synthetic compound (an imidazole derivative) that has been utilized for several decades.


Q: Can pets accidentally get into Slomin and what are the risks?

Official safety warnings state that Slomin must be stored out of the sight and reach of children and pets. Accidental ingestion, especially by small children or pets, is officially associated with a high risk of severe systemic reactions, including coma and slow heart rate. If accidental exposure occurs, official safety warnings indicate that immediate medical attention is required.


Q: Can Slomin worsen pre-existing mental health conditions?

Due to the drug's mechanism as a sympathomimetic (mimics adrenaline), it has the potential for rare systemic effects like insomnia. Official guidance recommends consulting a healthcare professional prior to use for individuals with pre-existing mental health conditions or those taking psychotropic medications.


Q: Does the effectiveness of Slomin change over time?

Yes, the effectiveness of Slomin can diminish with overuse. Regulatory documents caution that frequent or prolonged use can cause the original symptoms, such as nasal congestion, to become worse or recur, indicating a functional reduction in the product's efficacy.

How should Slomin be stored and disposed of?

How to Store and Dispose of Slomin

The storage and disposal of Slomin (Oxymetazoline) must align with official regulatory requirements to ensure product integrity and safety.

Storage Requirements

Slomin must be kept at controlled room temperature, generally defined as between 20 C and 25 C. It is mandatory to protect the medication from freezing and excessive heat.

Storage Constraint Requirement
Container Keep in the original container, tightly closed.
Protection Protect from light and excessive moisture.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Slomin should be disposed of via a drug take-back program. If this is unavailable, the product must be mixed with an undesirable substance and sealed in a bag before being placed in household trash. Do not dispose of this product by flushing it down a drain or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Slomin found in:

A-Z Index: